Haemonetics Corp (NYSE: HAE) kicked off on Tuesday, down -4.94% from the previous trading day, before settling in for the closing price of $82.92. Over the past 52 weeks, HAE has traded in a range of $47.31-$87.32.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 17.48%. While this was happening, its average annual earnings per share was recorded 7.54%. With a float of $46.05 million, this company’s outstanding shares have now reached $46.75 million.
Haemonetics Corp (HAE) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Haemonetics Corp is 1.62%, while institutional ownership is 110.93%. The most recent insider transaction that took place on Nov 10 ’25, was worth 98,784. In this transaction Director of this company bought 1,400 shares at a rate of $70.56, taking the stock ownership to the 24,757 shares. Before that another transaction happened on Jun 26 ’25, when Company’s Former Officer proposed sale 18,630 for $74.94, making the entire transaction worth $1,396,132.
Haemonetics Corp (HAE) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 1.19 earnings per share (EPS), higher than consensus estimate (set at 1.17) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.54% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.08% during the next five years compared to 17.48% growth over the previous five years of trading.
Haemonetics Corp (NYSE: HAE) Trading Performance Indicators
Take a look at Haemonetics Corp’s (HAE) current performance indicators. Last quarter, stock had a quick ratio of 1.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.78. Likewise, its price to free cash flow for the trailing twelve months is 14.41.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.43, a number that is poised to hit 1.25 in the next quarter and is forecasted to reach 5.48 in one year’s time.
